CSPC PHARMA Shares Surge Over 10% in Morning Trading as Key Phase III Trial Commences in China

Deep News06-29

Shares of CSPC PHARMA (01093) surged more than 10% in morning trading. At the time of writing, the stock was up 10.61% to HK$7.40, with a turnover of HK$662 million.

The company announced that its Phase III clinical trial for SYS6010 in combination with Enlansubai monoclonal antibody for the treatment of driver gene-negative non-small cell lung cancer (NSCLC), designated SYS6010–022 (SYNSTAR-04), has officially commenced in China. The first patient enrollment is projected for completion by July 2026. SYS6010 is an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR) developed by the group. It consists of a humanized anti-EGFR monoclonal antibody conjugated to a topoisomerase I inhibitor payload via a cleavable linker.

The SYS6010–022 (SYNSTAR-04) study is a randomized, open-label, multi-center Phase III trial designed to evaluate the efficacy and safety of SYS6010 combined with Enlansubai monoclonal antibody compared to immunotherapy plus platinum-based chemotherapy in patients with driver gene-negative, PD-L1 positive locally advanced or metastatic NSCLC. The group previously received feedback from the Center for Drug Evaluation of China's National Medical Products Administration in May 2026, agreeing to proceed with this clinical trial. Patient recruitment and screening are currently being actively advanced.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183414506?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 12:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183414506","market":"sg","top_or_hot":-1,"title":"CSPC PHARMA Shares Surge Over 10% in Morning Trading as Key Phase III Trial Commences in China","media":"Deep News","content":"<p>Shares of <b>CSPC PHARMA</b> (<b>01093</b>) surged more than 10% in morning trading. At the time of writing, the stock was up 10.61% to HK$7.40, with a turnover of HK$662 million.<br><br>\nThe company announced that its Phase III clinical trial for SYS6010 in combination with Enlansubai monoclonal antibody for the treatment of driver gene-negative non-small cell lung cancer (NSCLC), designated SYS6010–022 (SYNSTAR-04), has officially commenced in China. The first patient enrollment is projected for completion by July 2026. SYS6010 is an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR) developed by the group. It consists of a humanized anti-EGFR monoclonal antibody conjugated to a topoisomerase I inhibitor payload via a cleavable linker.<br><br>\nThe SYS6010–022 (SYNSTAR-04) study is a randomized, open-label, multi-center Phase III trial designed to evaluate the efficacy and safety of SYS6010 combined with Enlansubai monoclonal antibody compared to immunotherapy plus platinum-based chemotherapy in patients with driver gene-negative, PD-L1 positive locally advanced or metastatic NSCLC. The group previously received feedback from the Center for Drug Evaluation of China's National Medical Products Administration in May 2026, agreeing to proceed with this clinical trial. Patient recruitment and screening are currently being actively advanced.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC PHARMA Shares Surge Over 10% in Morning Trading as Key Phase III Trial Commences in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC PHARMA Shares Surge Over 10% in Morning Trading as Key Phase III Trial Commences in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-06-29 12:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>CSPC PHARMA</b> (<b>01093</b>) surged more than 10% in morning trading. At the time of writing, the stock was up 10.61% to HK$7.40, with a turnover of HK$662 million.<br><br>\nThe company announced that its Phase III clinical trial for SYS6010 in combination with Enlansubai monoclonal antibody for the treatment of driver gene-negative non-small cell lung cancer (NSCLC), designated SYS6010–022 (SYNSTAR-04), has officially commenced in China. The first patient enrollment is projected for completion by July 2026. SYS6010 is an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR) developed by the group. It consists of a humanized anti-EGFR monoclonal antibody conjugated to a topoisomerase I inhibitor payload via a cleavable linker.<br><br>\nThe SYS6010–022 (SYNSTAR-04) study is a randomized, open-label, multi-center Phase III trial designed to evaluate the efficacy and safety of SYS6010 combined with Enlansubai monoclonal antibody compared to immunotherapy plus platinum-based chemotherapy in patients with driver gene-negative, PD-L1 positive locally advanced or metastatic NSCLC. The group previously received feedback from the Center for Drug Evaluation of China's National Medical Products Administration in May 2026, agreeing to proceed with this clinical trial. Patient recruitment and screening are currently being actively advanced.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1008478684.HKD","symbol_name":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","start_time":0,"source_url":"","article_id":"1183414506","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183414506","pubTimestamp":1782705635,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Shares of CSPC PHARMA (01093) surged more than 10% in morning trading. At the time of writing, the stock was up 10.61% to HK$7.40, with a turnover of HK$662 million. The company announced that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","IE0008368742.USD":"首域中国增长基金I Acc","01093":"石药集团","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","BK1521":"挪威政府全球养老基金持仓","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","BK1191":"制药","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU0140636845.USD":"施罗德大中华区股票A Acc","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","BK1515":"抗疫概念","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC"},"translate_title":"随着关键III期试验在中国开始，石药集团股价早盘飙升逾10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"Shares of CSPC PHARMA (01093) surged more than 10% in morning trading. At the time of writing, the stock was up 10.61% to HK$7.40, with a turnover of HK$662 million.\nThe company announced that its Phase III clinical trial for SYS6010 in combination with Enlansubai monoclonal antibody for the treatment of driver gene-negative non-small cell lung cancer (NSCLC), designated SYS6010–022 (SYNSTAR-04), has officially commenced in China. The first patient enrollment is projected for completion by July 2026. SYS6010 is an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR) developed by the group. It consists of a humanized anti-EGFR monoclonal antibody conjugated to a topoisomerase I inhibitor payload via a cleavable linker.\nThe SYS6010–022 (SYNSTAR-04) study is a randomized, open-label, multi-center Phase III trial designed to evaluate the efficacy and safety of SYS6010 combined with Enlansubai monoclonal antibody compared to immunotherapy plus platinum-based chemotherapy in patients with driver gene-negative, PD-L1 positive locally advanced or metastatic NSCLC. The group previously received feedback from the Center for Drug Evaluation of China's National Medical Products Administration in May 2026, agreeing to proceed with this clinical trial. Patient recruitment and screening are currently being actively advanced.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183414506","isCrawlerRequest":true}